Please login to the form below

Not currently logged in
Email:
Password:

Sanofi-aventis in merger talks with Genzyme

Sanofi-aventis has announced that it is in discussions with Genzyme, and has offered to acquire the company for $18.5bn, or $69 a share

Sanofi-aventis (S-A) has announced that it is in discussions with Genzyme, producer of drugs for rare diseases and has offered to acquire the company for $18.5bn, or $69 a share. Genzyme has stated that the figure is too low and the two companies are looking at a way to bridge the valuation gap with a potential contingent value right (CVR) for multiple sclerosis drug alemtuzumab, which the US biotech company plans to brand as Lemtrada.

S-A first sent a letter to Genzyme's management last July. It launched the tender offer, which expires on January 21, after failing to engage Genzyme executives in talks.

Financial advisers for the two companies are discussing the value of a CVR that would take the total Genzyme offer to around $80 per share from $69 at present if it meets certain milestones, giving the US target a total value of $20.7bn.

A representative from S-A said: "Those discussions are continuing and now include representatives from both companies. There remain significant differences on the terms and conditions of the potential CVR and the value of our offer, and there is no guarantee that the parties will come to an agreement."

A contingent value right, or CVR, is often used when buyers and sellers can't agree on a purchase price and usually kicks in after an acquired company meets sales or regulatory targets.

10th January 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics